Skip to main content
TipRanks
Go Ultimate75% OFF

Arcus Biosciences (RCUS) AI Stock Analysis

550 Followers
RCUS

Arcus Biosciences

(NYSE:RCUS)

Select Model
Rating:48Neutral
Price Target:$15.50▼(-0.77% Downside)
Action:reiterated
Date:11/05/26

The score is held down primarily by weak financial performance (large and worsening losses plus heavy cash burn) and bearish technicals (price below key moving averages with negative MACD and weak RSI). Offsetting factors include a constructive earnings call with defined clinical catalysts and stated runway into H2 2028, alongside supportive corporate events (capital raise and positive ARC-20 data), but these do not fully counterbalance the current profitability and cash flow risks.

Positive Factors
Clinical validation and kidney-cancer pipelineThe ARC-20 results provide clinical support for casdatifan across first-, second- and late-line kidney-cancer settings. Durable activity and an acceptable reported safety profile can strengthen the program’s competitive position and support broader development if later trials confirm these findings.
Negative Factors
Severe cash burnThe scale of operating and free-cash-flow losses shows that Arcus currently consumes substantial capital to fund development. Persistent outflows increase reliance on collaboration receipts or external financing and could constrain flexibility if clinical programs take longer or require greater spending.

Arcus Biosciences Key Performance Indicators (KPIs)

Revenue by SegmentBreaks down revenue by different business units or product lines, highlighting which areas are driving growth and which may need strategic adjustments.

$0.00$100.00M$200.00M$300.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Revenue is clearly lumpy and milestone-driven: large, infrequent license/development receipts drive the peaks while “Other Collaboration” provides a small, shrinking baseline—so GAAP revenue is timing-dependent, not recurring. Management’s reiterated $50–65M guidance and strong cash runway ease financing concerns, but planned R&D cuts and portfolio focus on cascadifan mean baseline collaboration receipts may decline. In short, treat near-term revenue as binary milestone noise tied to partner payments and clinical catalysts (PEEK‑1/other readouts), not as evidence of durable commercial traction.

Data provided by:The Fly

Arcus Biosciences (RCUS) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%30%40%RCUS-35.67%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$2.25B
Dividend Yield
―
Average Volume (3M)
1.85M
Price to Earnings (P/E)
-4.3
Beta (1Y)
1.42
Revenue Growth
-58.33%
EPS Growth
-6.14%
Country
US
Employees
601
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Arcus Biosciences Business Overview & Revenue Model

Company Description

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney ca...

How the Company Makes Money

Arcus Biosciences does not primarily generate revenue from commercial product sales because, as a clinical-stage company, it has not historically relied on approved, marketed drugs as a core earnings base (commercial product revenue information: null...

Arcus Biosciences Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q2-2026)|% Change Since:-43.61%|Next Earnings Date:Mar 02, 2027
Earnings Call SentimentPositive

The call emphasized multiple substantial clinical and business positives: strong translational validation (Nature paper), robust development progress for casdatifan with clear registrational timelines (PEAK‑1 enrollment on track and PEAK‑20 planned), multiple strategic collaborations, a broad immunology pipeline with near‑term IND milestones (AB102, TNFR1), and a solid cash runway into H2 2028. Key near‑term risks include a meaningful quarter‑over‑quarter cash reduction (~11.5%), expected declines in collaboration revenue from the Gilead wind‑down, high R&D spend with planned concentration (>80%) on casdatifan by 2027, and dependence on upcoming clinical readouts to validate the growth and revenue thesis. On balance, the highlights — clinical progress, partnerships, translational evidence, and adequate runway — outweigh the lowlights, which are primarily financial/timing and execution risks.

Positive Updates

Casdatifan Market Opportunity and Peak Sales Outlook
Management projects a total peak sales opportunity for casdatifan of $5–$10 billion, citing RCC sales in major markets expected to reach roughly $13 billion by 2030. Specific line opportunities highlighted: ~20,000 IO‑experienced patients (~$2B opportunity) and >$4B first‑line opportunity.

Negative Updates

Quarterly Cash Decline
Cash and investments decreased from $876M at the end of Q1 to $775M at June 30, 2026 — a decline of $101M (~11.5%) quarter‑over‑quarter, though management still forecasts runway into H2 2028.

Company Guidance

Management provided specific near- and medium-term guidance: as of June 30, 2026 Arcus had $775M cash and investments (down from $876M at March 31), expects to end 2026 with ~ $600M and to have runway into at least H2 2028; Q2 GAAP revenue was $41M with full-year 2026 GAAP revenue guided to $65–75M; Q2 R&D expense was $113M (net) with R&D expected to meaningfully decline in 2026–27 and >80% of 2027 portfolio spend directed to casdatifan, G&A was $24M and non-cash stock‑based comp $15M in Q2. Clinical and commercial timelines: PEAK‑1 (cas + cabozantinib) remains on track to complete enrollment by year‑end 2026, PEAK‑20 (first‑line registrational trial) to start by year‑end 2026, ARC‑20 will deliver a broad October data package from >200 patients (including a first‑line cas+zim cohort with 30 patients and a 7% primary progression rate, a cas+zim ORR readout with ~11 months follow‑up, a second‑line cas+cabo cohort of ~45 patients with ≥18 months follow‑up, and ~120 late‑line monotherapy patients with ~28 months median follow‑up), PRISM‑1 (quemliclustat in pancreatic cancer) is expected to read out in H1 next year, AB102 dosing begins this month with PK data in Q4 and a TNFR1 program entering clinic in early 2027. Finally, market and value context: Arcus projects RCC sales in major markets to reach ~$13B by 2030, estimates PEAK‑1 addresses ~20,000 IO‑experienced patients (> $2B opportunity), first‑line > $4B, and total peak sales opportunity for casdatifan of $5–10B.

Arcus Biosciences Financial Statement Overview

Summary

Fundamentals are weak: revenue is down (~14.5% TTM) while operating losses are very large (TTM operating loss ~$475M) and widening, and cash burn is substantial (TTM operating cash flow and FCF both around -$465M). Balance sheet leverage is moderate (debt-to-equity ~0.28), but equity has fallen meaningfully and returns remain sharply negative, underscoring ongoing financing dependence.

Income Statement

22Negative

Balance Sheet

58Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue100.00M247.00M258.00M117.00M112.00M383.00M
Gross Profit95.00M237.00M258.00M117.00M112.00M383.00M
EBITDA-412.00M-335.00M-269.00M-291.00M-258.00M59.00M
Net Income-445.00M-353.00M-283.00M-307.00M-267.00M53.00M
Balance Sheet
Total Assets818.00M1.14B1.15B1.09B1.34B1.59B
Cash, Cash Equivalents and Short-Term Investments630.00M981.00M978.00M759.00M1.01B499.31M
Total Debt116.00M112.00M60.00M11.00M120.00M121.99M
Total Liabilities460.00M508.00M665.00M633.00M688.00M750.45M
Stockholders Equity358.00M631.00M485.00M462.00M657.00M841.45M
Cash Flow
Free Cash Flow-466.00M-484.00M-176.00M-330.00M432.00M-282.25M
Operating Cash Flow-465.00M-482.00M-170.00M-306.00M438.00M-256.17M
Investing Cash Flow66.00M66.00M-84.00M194.00M-413.00M-3.87M
Financing Cash Flow312.00M488.00M277.00M33.00M33.00M237.34M

Arcus Biosciences Technical Analysis

Technical Analysis SentimentNegative
Last Price15.62

Price Trends

50DMA21.47Negative
100DMA25.19Negative
200DMA24.34Negative

Market Momentum

MACD-1.58Positive
RSI28.58Positive
STOCH1.83Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RCUS, the sentiment is Negative. The current price of 15.62 is below the 20-day moving average (MA) of 17.76, below the 50-day MA of 21.47, and below the 200-day MA of 24.34, indicating a bearish trend. The MACD of -1.58 indicates Positive momentum. The RSI at 28.58 is Positive, neither overbought nor oversold. The STOCH value of 1.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RCUS.

Arcus Biosciences Risk Analysis

Arcus Biosciences disclosed 61 risk factors in its most recent earnings report. Arcus Biosciences reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement with Hercules Capital, Inc., as amended, and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business.Q4, 2025
2.We may fail to obtain orphan drug designations from the FDA for our investigational products, and even if we obtain such designations, we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.Q4, 2025
3.Any difficulties or delays in the commencement or completion, or the termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue or adversely affect our commercial prospects.Q4, 2024

Arcus Biosciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

RCUS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
LEGNLEGN63Neutral$3.12B-1525.00-0.02%―49.73%98.75%
NRIXNRIX61Neutral$1.49B5.1249.34%―738.76%―
XNCRXNCR61Neutral$2.55B-21.18-21.29%―33.55%11.51%
IMCRIMCR60Neutral$1.38B-41.73-7.96%―13.01%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
RCUSRCUS48Neutral$2.27B-4.27-90.04%―-58.33%-6.14%
CRSPCRSP42Neutral$3.78B-8.25-25.59%―-34.34%14.92%

* Healthcare Sector Average

Performance Comparison

0%50%100%RCUSXNCRCRSPLEGNNRIXIMCRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
RCUS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RCUSArcus Biosciences15.62-7.56-32.61%
XNCRXencor Inc.33.2616.5298.69%
CRSPCrispr Therapeutics39.10-12.15-23.71%
LEGNLegend Biotech Corporation15.25-11.90-43.83%
NRIXNurix Therapeutics, Inc.12.85-4.30-25.07%
IMCRImmunocore Holdings Plc26.41-12.28-31.74%

Arcus Biosciences Corporate Events

Business Operations and StrategyPrivate Placements and Financing

Arcus Biosciences Completes $269 Million Common Stock Offering

Positive
Oct 23, 2026

On October 21, 2026, Arcus Biosciences, Inc. entered into an underwriting agreement with a syndicate of investment banks for a public offering of its common stock at a price of $17.50 per share, including an option for underwriters to purchase additi...

Business Operations and StrategyProduct-Related Announcements

Arcus Biosciences unveils promising kidney cancer data

Positive
Oct 20, 2026

On October 20, 2026, Arcus Biosciences reported new data from its ARC-20 platform study of casdatifan-based regimens in clear cell renal cell carcinoma, covering first-, second- and late-line settings as of a September 4, 2026 cutoff. First-line TKI-...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026